Could Intersect ENT, Inc. (XENT) Go Down After Achieving 52-Week High?

April 17, 2018 - By Kenneth Lin

Intersect ENT, Inc. (NASDAQ:XENT) Logo

The stock of Intersect ENT, Inc. (NASDAQ:XENT) hit a new 52-week high and has $44.14 target or 7.00 % above today’s $41.25 share price. The 5 months bullish chart indicates low risk for the $1.23 billion company. The 1-year high was reported on Apr, 17 by If the $44.14 price target is reached, the company will be worth $86.03 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 1.10% or $0.45 during the last trading session, reaching $41.25. About 35,219 shares traded. Intersect ENT, Inc. (NASDAQ:XENT) has risen 124.86% since April 17, 2017 and is uptrending. It has outperformed by 113.31% the S&P500.

Analysts await Intersect ENT, Inc. (NASDAQ:XENT) to report earnings on May, 1. They expect $-0.23 earnings per share, 0.00 % or $0.00 from last year’s $-0.23 per share. After $-0.11 actual earnings per share reported by Intersect ENT, Inc. for the previous quarter, Wall Street now forecasts 109.09 % negative EPS growth.

Intersect ENT, Inc. (NASDAQ:XENT) Ratings Coverage

Among 3 analysts covering Intersect ENT (NASDAQ:XENT), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Intersect ENT had 4 analyst reports since November 6, 2017 according to SRatingsIntel. The stock of Intersect ENT, Inc. (NASDAQ:XENT) earned “Buy” rating by Canaccord Genuity on Thursday, January 4. Canaccord Genuity maintained it with “Buy” rating and $36.0 target in Wednesday, December 6 report. The rating was upgraded by JP Morgan to “Overweight” on Tuesday, January 2.

Intersect ENT, Inc., a commercial stage drug-device company, provides therapeutic solutions for patients with ear, nose, and throat conditions in the United States. The company has market cap of $1.23 billion. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It currently has negative earnings. The firm is also developing RESOLVE, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting.

Intersect ENT, Inc. (NASDAQ:XENT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: